MAPA–MAPS Medical Affairs Summit 2023: highlights report
This year’s Medical Affairs Professionals of Australasia (MAPA) and Medical Affairs Professional Society (MAPS) Medical Affairs Summit was held from 8 to 10 November 2023 in Sydney, Australia.
Featured
24 January 2024
ACCORD: new guideline to support consistent and complete reporting of consensus methods in biomedical research
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
All
- All
- News
- Articles
- Events
Medical Affairs Communications Team of the Year: Oxford PharmaGenesis colleagues win prestigious 2023 PharmaTimes award
Congratulations to Oxford PharmaGenesis colleagues who were named Medical Affairs Communications Team of the Year at the PharmaTimes gala dinner and awards ceremony on Thursday 16 November!
MS Brain Health highly commended for PRIME Award for Sustained Excellence in recognition of the impact of its policy recommendations
Oxford PharmaGenesis, Oxford Health Policy Forum and MS Australia are celebrating the shortlisting of MS Brain Health for a PRIME Award for Sustained Excellence, and are incredibly proud to have been highly commended at the award ceremony. The awards took place in Sydney, Australia, on Thursday 9 November 2023. The PRIME Awards recognize and celebrate…
Oxford PharmaGenesis sponsors global HIFA-WHO consultation to promote reliable healthcare information
Oxford PharmaGenesis is proud to sponsor a global consultation, run by Healthcare Information For All (HIFA) in partnership with the World Health Organization (WHO), to accelerate progress towards universal access to reliable healthcare information. Every day, tens of thousands of children and adults die needlessly for want of simple, low-cost interventions, which are often locally…
Find us at ISPOR Europe 2023
HEOR and market access are evolving, with big changes in HTA around the corner, acceleration in the use of RWE and increased reactions to cost-containment measures. We are contributing to conversations about how these changes affect value demonstration strategies. At Oxford PharmaGenesis, we are experts in advising on payer strategy, developing payer evidence and supporting payer evaluation. We understand differences in payer evidence needs, and we know how to create compelling value stories for our clients that achieve powerful results.
Benchmarking open access in publications with authors affiliated to pharma companies and universities
Many scientific and medical publications lie behind a paywall. New medical research is increasingly being published as ‘open access’, which makes articles freely available to anyone. This provides major benefits because it gives researchers and members of the public equal access to medical knowledge. It also improves research transparency, which helps to foster public trust.
